DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Planchard D, Groen HJM, Kim TM et al.
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
J Clin Oncol 2015; (suppl): abstr 8006
33
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.